Related conditions
A practical approach to the diagnosis of systemic amyloidoses.
Fernández de Larrea C et al. Blood. 2015 Jan 30. pii: blood-2014-11-609883. [Epub ahead of print]
Emerging treatments
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Mikhael JR et al. Br J Haematol. 2015 Feb 13. doi: 10.1111/bjh.13296. [Epub ahead of print]. Everolimus (RAD001) Activity in Relapsed and/or Refractory Multiple Myeloma: A Phase I Study. Guenther A et al. Haematologica. 2015 Feb 14. pii: haematol.2014.116269. [Epub ahead of print]. Phase I/II Study of the Combination…
Biology and genetics
Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. Anastasiadou E et al. Int J Cancer. 2015 Feb 20. doi: 10.1002/ijc.29489. [Epub ahead of print]. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Dai Y et al. Autophagy. 2015 Feb 20:0. [Epub ahead of print]. Hyaluronan synthase 1: a mysterious enzyme with unexpected functions. Siiskonen H et…
Supportive care
OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Holtick U et al. Eur J Haematol. 2015 Feb 23. doi: 10.1111/ejh.12541. [Epub ahead of print]. Use of allogeneic platelet gel in the management of chemotherapy extravasation injuries: a case report. Di Costanzo G et al. Onco…
General
The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Hostenkamp G et al. Soc Sci Med. 2015 Feb 7;130C:162-171. doi: 10.1016/j.socscimed.2015.02.003. [Epub ahead of print]. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E et al. J Oncol Pharm Pract. 2015 Feb 17. pii: 1078155215572036. [Epub ahead of print]. Advance…
Complications of myeloma and its treatments
Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment. Wang L et al. Clin J Oncol Nurs. 2015 Feb 1;19(1):E4-7. doi: 10.1188/15.CJON.E4-E7. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Peng L et al. Support Care Cancer. 2015 Feb 13. [Epub ahead of print]. Renal insufficiency retains adverse prognostic implications despite renal function improvement following…
Current treatments
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Harrison SJ et al. Am J Hematol. 2015 Feb 4. doi: 10.1002/ajh.23967. [Epub ahead of print].
Diagnostic tests and prognostic indicators
18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study. Fonti R et al. Clin Nucl Med. 2015 Jan 20. [Epub ahead of print]. Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Dimopoulos MA et al. J Clin Oncol. 2015 Jan 20. pii: JCO.2014.57.9961. [Epub…
Related conditions
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Katayama K et al. BMJ Open. 2015 Jan 8;5(1):e007330. doi: 10.1136/bmjopen-2014-007330.
Emerging treatments
Multiple Myeloma Yields to CD38 Inhibitors. [No authors listed]. Cancer Discov. 2015 Jan 16. [Epub ahead of print]. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Atrash S et al. Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. Mangiacavalli S et al. Leuk…